What happened
On September 7, MicroTech Medical (02235) announced that its new-generation split-type continuous glucose monitoring system, AiDEX G9, has received market approval from China's National Medical Products Administration.
The product introduces an innovative change in technical architecture compared to the first-generation split-type device, with upgrades in size, lightness, and wearing comfort.
The system aims to provide diabetic patients with a lighter and more confident blood glucose management experience.
Why it matters
This approval marks a significant step for MicroTech Medical in advancing diabetes care technology, potentially improving patient adherence and quality of life through enhanced comfort and design.
The technical overhaul suggests a competitive push in the CGM market, where user experience is a key differentiator.
Key facts
The AiDEX G9 is a new-generation split-type continuous glucose monitoring system.
It received market approval from the National Medical Products Administration.
The product features upgrades in volume, lightness, and wearing comfort compared to the first-generation model.
What to watch next
Market reception and adoption rates of the AiDEX G9 among diabetic patients.
Potential competitive responses from other CGM manufacturers in China.